- Home
- IVP vs INDP Comparison
IVP vs INDP Comparison
Compare IVP & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- INDP
- Stock Information
- Founded
- IVP 2020
- INDP 2000
- Country
- IVP United States
- INDP United States
- Employees
- IVP N/A
- INDP N/A
- Industry
- IVP Diversified Commercial Services
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- INDP Health Care
- Exchange
- IVP Nasdaq
- INDP Nasdaq
- Market Cap
- IVP 3.5M
- INDP 4.0M
- IPO Year
- IVP 2023
- INDP N/A
- Fundamental
- Price
- IVP $0.88
- INDP $3.63
- Analyst Decision
- IVP
- INDP Strong Buy
- Analyst Count
- IVP 0
- INDP 2
- Target Price
- IVP N/A
- INDP $238.00
- AVG Volume (30 Days)
- IVP 123.8K
- INDP 574.0K
- Earning Date
- IVP 11-12-2025
- INDP 11-11-2025
- Dividend Yield
- IVP N/A
- INDP N/A
- EPS Growth
- IVP N/A
- INDP N/A
- EPS
- IVP N/A
- INDP N/A
- Revenue
- IVP $15,292,904.00
- INDP N/A
- Revenue This Year
- IVP N/A
- INDP N/A
- Revenue Next Year
- IVP N/A
- INDP N/A
- P/E Ratio
- IVP N/A
- INDP N/A
- Revenue Growth
- IVP N/A
- INDP N/A
- 52 Week Low
- IVP $0.63
- INDP $2.22
- 52 Week High
- IVP $8.00
- INDP $47.60
- Technical
- Relative Strength Index (RSI)
- IVP 40.92
- INDP 47.48
- Support Level
- IVP $0.85
- INDP $3.41
- Resistance Level
- IVP $1.01
- INDP $4.00
- Average True Range (ATR)
- IVP 0.05
- INDP 0.63
- MACD
- IVP -0.01
- INDP 0.04
- Stochastic Oscillator
- IVP 19.44
- INDP 32.19
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.